{"config":{"lang":["en"],"separator":"[\\s\\-]+","pipeline":["stopWordFilter"],"fields":{"title":{"boost":1000.0},"text":{"boost":1.0},"tags":{"boost":1000000.0}}},"docs":[{"location":"","title":"Welcome to Your Patient Registry Data Sharing Ecosystem Template","text":"<p>This open-source website template is designed to help patient registry teams create a professional, public-facing portal for sharing information about their data, governance policies, and access procedures.</p> <p>Built with MkDocs and the Material for MkDocs theme, this site supports transparent, ethical, and well-documented data sharing \u2014 even if your team has limited technical resources.</p>"},{"location":"#whats-included","title":"\ud83c\udf1f What\u2019s Included","text":"<p>The template comes with pre-built pages and sample language for:</p> <ul> <li>A Data Dictionary outlining available variables</li> <li>Derived Fields describing calculated or harmonized data</li> <li>Information for Researchers, including:<ul> <li>Data Use Agreement (DUA) and access instructions</li> <li>IRB and ethical oversight documentation</li> <li>End User Survey to assess technical and governance needs</li> <li>Sharing platforms, data environments, and omics considerations</li> </ul> </li> <li>A Data Sharing Readiness checklist to help registry teams prepare documentation, inventories, and governance for sharing</li> <li>A visual Data Access Process for user guidance that you can modify and convert to a flow chart</li> <li>Sample FAQs, Acknowledgments, and policy references</li> <li>A curated Key Resources page for external guidance and learning, including NIH, FDA, and EMA sources</li> </ul>"},{"location":"#potential-use-cases-for-shared-registry-data","title":"\ud83e\uddea Potential Use Cases for Shared Registry Data","text":"<p>This section helps you explain how your registry data can support meaningful research, translational science, and clinical discovery. Example use cases:</p>"},{"location":"#academic-research","title":"Academic Research","text":"<ul> <li>Analyze disease progression or treatment patterns</li> <li>Explore demographic or clinical subgroup trends</li> <li>Conduct retrospective observational studies</li> <li>Correlate clinical data with biospecimen-based phenotyping</li> <li>Integrate registry data with genomic, transcriptomic, or proteomic analyses</li> </ul>"},{"location":"#clinical-quality-benchmarking","title":"Clinical &amp; Quality Benchmarking","text":"<ul> <li>Compare outcomes across sites or networks</li> <li>Identify variation in care delivery</li> <li>Generate insights to inform care improvement initiatives</li> </ul>"},{"location":"#industry-collaboration","title":"Industry Collaboration","text":"<ul> <li>Design trials with real-world inclusion and exclusion criteria</li> <li>Discover unmet clinical or diagnostic needs</li> <li>Use real-world data to identify biomarkers or stratify patient populations</li> </ul>"},{"location":"#public-health-policy","title":"Public Health &amp; Policy","text":"<ul> <li>Estimate disease prevalence or geographic distribution</li> <li>Model healthcare utilization or economic burden</li> <li>Inform guideline development or public health strategies</li> </ul> <p>\u2728 Your team can edit or expand this list to reflect your registry\u2019s goals.</p>"},{"location":"#built-for-customization","title":"\ud83d\udee0\ufe0f Built for Customization","text":"<p>You can fully adapt the site to match your registry:</p> <ul> <li>Swap in your own content and structure</li> <li>Update branding and page layout</li> <li>Add new tabs or link to external sites</li> <li>Publish via GitHub Pages or other hosting platforms</li> </ul> <p>See the How to Customize This Template guide for setup instructions.</p>"},{"location":"#disclaimer","title":"\u26a0\ufe0f Disclaimer","text":"<p>All content is provided for demonstration only. Registry teams must ensure final language aligns with local regulations and IRB-reviewed protocols.</p>"},{"location":"#license-and-attribution","title":"\ud83d\udd13 License and Attribution","text":"<p>This project is available under CC BY 4.0. You may copy, reuse, or adapt it for your own registry \u2014 just include proper attribution.</p> <p>Let\u2019s build a culture of transparent, ethical, and collaborative data sharing in patient-centered research.</p>"},{"location":"DACSOP/","title":"Standard Operating Procedures","text":""},{"location":"DACSOP/#data-access-committee-dac","title":"Data Access Committee (DAC)","text":""},{"location":"DACSOP/#1-introduction","title":"1. Introduction","text":"<p>The Data Access Committee (DAC) is established to review, assess, and decide on third-party requests for access to data held within a registry or data repository (\u201cthe Registry\u201d). The DAC ensures that access to Registry data is granted in accordance with established policies, ethical principles, and applicable data protection regulations.</p> <p>Different levels of data access authorization\u2014based on the type of data requested, the nature of the requestor, and the intended purpose of use\u2014are defined in the Registry\u2019s Data Access Policy (DAP).</p> <p>This document describes the operating procedures of the DAC to promote transparency, consistency, accountability, and compliance.</p>"},{"location":"DACSOP/#2-composition-of-the-dac","title":"2. Composition of the DAC","text":""},{"location":"DACSOP/#21-dac-co-chairs","title":"2.1 DAC Co-Chairs","text":"<ul> <li>The DAC is led by two Co-Chairs appointed by the Registry\u2019s governing or steering body.</li> <li>The Co-Chairs provide strategic oversight and ensure that DAC decisions align with the   mission and objectives of the Registry.</li> <li>Co-Chairs may represent complementary perspectives (e.g. scientific, clinical, or   participant/community representation).</li> </ul>"},{"location":"DACSOP/#22-dac-members","title":"2.2 DAC Members","text":"<p>The DAC is composed of members with expertise relevant to the Registry, which may include:</p> <ul> <li>A representative of Registry data contributors or participating sites</li> <li>A subject-matter or domain expert relevant to the data access request</li> <li>A patient, public, or community representative, where applicable</li> </ul> <p>Membership may be adapted depending on the scope and nature of individual requests.</p>"},{"location":"DACSOP/#23-dac-secretariat","title":"2.3 DAC Secretariat","text":"<ul> <li>The DAC is supported by a Secretariat responsible for coordinating DAC activities,   managing communications, and maintaining records.</li> <li>The Secretariat serves as the primary point of contact for data requestors.</li> </ul>"},{"location":"DACSOP/#24-rotation-and-review","title":"2.4 Rotation and Review","text":"<ul> <li>DAC membership may follow a rotation system to ensure continuity, availability, and   appropriate representation.</li> <li>The composition and leadership of the DAC are reviewed at least every three years,   or earlier if required.</li> </ul>"},{"location":"DACSOP/#25-ad-hoc-expertise","title":"2.5 Ad Hoc Expertise","text":"<ul> <li>The DAC may seek additional expertise on an ad hoc basis to support the evaluation of   specific requests.</li> <li>This may include scientific, technical, ethical, legal, or data protection expertise.</li> </ul>"},{"location":"DACSOP/#3-responsibilities-of-the-dac","title":"3. Responsibilities of the DAC","text":"<p>The DAC is responsible for:</p> <ul> <li>Reviewing and evaluating all data access requests submitted to the Registry (see sample DAC evaluation rubric here.</li> <li>Ensuring that requests align with the Registry\u2019s objectives and Data Access Policy</li> <li>Determining appropriate access levels (e.g. aggregate, pseudonymized, or limited datasets)</li> <li>Verifying that requestors are appropriately qualified and authorized</li> <li>Confirming that required ethical, institutional, or regulatory approvals are in place</li> <li>Reviewing and validating proposed data queries or access mechanisms, where applicable</li> <li>Identifying overlaps with existing projects and encouraging collaboration</li> <li>Communicating decisions and conditions clearly and in a timely manner</li> <li>Reporting DAC activities and decisions to the Registry\u2019s governing body</li> </ul>"},{"location":"DACSOP/#4-data-access-request-process","title":"4. Data Access Request Process","text":"<ol> <li> <p>Submission    Data requestors submit a completed Data Access Request Form for each proposed project.</p> </li> <li> <p>Administrative Review    The DAC Secretariat performs an initial review to confirm completeness and eligibility.    Clarifications or additional information may be requested.</p> </li> <li> <p>DAC Review    Complete requests are submitted to the DAC for evaluation. The DAC may request further    clarification from the applicant.</p> </li> <li> <p>Decision and Feedback    The DAC approves, conditionally approves, or rejects the request and provides written    feedback outlining any conditions or recommendations.</p> </li> <li> <p>Data Use Agreement    Prior to any data transfer or access, approved requestors must sign a Data Transfer    Agreement (DTA) or Data Use Agreement specifying permitted uses, restrictions, and    data protection obligations.</p> </li> </ol>"},{"location":"DACSOP/#5-meetings-and-decision-making","title":"5. Meetings and Decision-Making","text":"<ul> <li>The DAC meets at regular or ad hoc intervals depending on the volume and urgency of   requests.</li> <li>The Secretariat circulates relevant documentation in advance of meetings.</li> <li>The DAC Co-Chairs chair meetings and facilitate discussions.</li> <li>In the absence of one Co-Chair, the other assumes full responsibility.</li> <li>Decisions are made by consensus where possible; otherwise, voting procedures defined   by the DAC apply.</li> <li>Each DAC member typically has one vote.</li> <li>All decisions, including declared conflicts of interest, are documented by the Secretariat.</li> </ul>"},{"location":"DACSOP/#6-conflicts-of-interest","title":"6. Conflicts of Interest","text":"<ul> <li>DAC members must declare any actual or perceived conflicts of interest related to a   specific data access request.</li> <li>Non-conflicted members determine whether recusal is required.</li> <li>Recused members do not participate in discussions or decisions and do not access   related confidential materials.</li> </ul>"},{"location":"DACSOP/#7-confidentiality-and-data-security","title":"7. Confidentiality and Data Security","text":"<ul> <li>DAC members must maintain confidentiality regarding data access requests and   deliberations.</li> <li>All documents are stored and managed using secure systems.</li> <li>Data access is restricted to authorized parties in accordance with approved procedures   and agreements.</li> </ul>"},{"location":"DACSOP/#8-review-and-revision","title":"8. Review and Revision","text":"<ul> <li>These SOPs are reviewed periodically to ensure continued relevance and effectiveness.</li> <li>Revisions are approved by the Registry\u2019s governing or steering body.</li> </ul>"},{"location":"DACSOP/#9-contact-information","title":"9. Contact Information","text":"<p>For inquiries regarding data access requests or DAC operations, contact the DAC Secretariat:</p> <p>[Insert contact information]</p>"},{"location":"DACSOP/#10-approval","title":"10. Approval","text":"<p>These Standard Operating Procedures are approved by the Registry\u2019s governing body and take effect as of [Insert date].</p>"},{"location":"DACSOP/#references-and-further-learning","title":"References and Further Learning","text":"<p>The following resources provide additional background and guidance on data access governance and responsible data sharing. They are provided for informational purposes and are not required to adopt or implement this SOP.</p>"},{"location":"DACSOP/#reference-sops","title":"Reference SOPs","text":"<ul> <li>ERN EURO-NMD. Standard Operating Procedures \u2013 Data Access Committee (DAC), Version 1.0   https://ern-euro-nmd.eu/wp-content/uploads/2024/06/SOP-DAC-v1.0-vf.pdf   The template SOP above was adapted from this source.</li> </ul>"},{"location":"DACSOP/#further-learning","title":"Further Learning","text":"<ul> <li> <p>Global Alliance for Genomics and Health (GA4GH)   Data access governance, data use conditions, and responsible sharing frameworks   https://www.ga4gh.org</p> </li> <li> <p>ELIXIR   Governance models, data stewardship, and access policies for life science data   https://elixir-europe.org</p> </li> </ul>"},{"location":"DACrubric/","title":"Data Access Request Evaluation Rubric","text":""},{"location":"DACrubric/#for-use-by-the-data-access-committee-dac","title":"For Use by the Data Access Committee (DAC)","text":""},{"location":"DACrubric/#purpose","title":"Purpose","text":"<p>This rubric supports consistent, transparent, and proportionate evaluation of data access requests. It is intended for use by DAC members when reviewing applications for access to registry or repository data.</p> <p>The rubric may be adapted to local legal, ethical, and operational requirements.</p>"},{"location":"DACrubric/#how-to-use-this-rubric","title":"How to Use This Rubric","text":"<ul> <li>Each criterion should be assessed independently.</li> <li>Criteria may be scored qualitatively or numerically, depending on DAC practice.</li> <li>Not all criteria carry equal weight; higher scrutiny should be applied to requests   involving more sensitive data or higher risk.</li> <li>The DAC may approve, conditionally approve, or reject a request based on the   overall assessment.</li> </ul>"},{"location":"DACrubric/#1-requestor-eligibility-and-capacity","title":"1. Requestor Eligibility and Capacity","text":"Criterion Assessment Considerations Rating Identity and affiliation Is the requestor clearly identified and affiliated with a legitimate institution or organisation? \u2610 Satisfactory \u2610 Needs clarification \u2610 Unsatisfactory Qualifications and expertise Does the requestor have appropriate expertise to use the data responsibly? \u2610 Satisfactory \u2610 Needs clarification \u2610 Unsatisfactory Role clarity Are the roles and responsibilities of all team members clearly described? \u2610 Satisfactory \u2610 Needs clarification \u2610 Unsatisfactory"},{"location":"DACrubric/#2-scientific-public-or-societal-value","title":"2. Scientific, Public, or Societal Value","text":"Criterion Assessment Considerations Rating Purpose of the request Is the purpose clearly stated and appropriate for the Registry\u2019s mission? \u2610 Satisfactory \u2610 Needs clarification \u2610 Unsatisfactory Value and relevance Does the project demonstrate scientific, public health, or societal value? \u2610 Satisfactory \u2610 Needs clarification \u2610 Unsatisfactory Avoidance of duplication Does the request overlap with existing or ongoing projects? If so, is this justified or coordinated? \u2610 Satisfactory \u2610 Needs clarification \u2610 Unsatisfactory"},{"location":"DACrubric/#3-data-requested-and-proportionality","title":"3. Data Requested and Proportionality","text":"Criterion Assessment Considerations Rating Data minimisation Is the amount and type of data requested proportionate to the stated aims? \u2610 Satisfactory \u2610 Needs clarification \u2610 Unsatisfactory Sensitivity of data Does the request involve sensitive, rare, or potentially identifiable data? \u2610 Low \u2610 Moderate \u2610 High Access level requested Is the requested access level (e.g. aggregate, pseudonymized) appropriate? \u2610 Satisfactory \u2610 Needs clarification \u2610 Unsatisfactory"},{"location":"DACrubric/#4-ethical-and-regulatory-compliance","title":"4. Ethical and Regulatory Compliance","text":"Criterion Assessment Considerations Rating Ethics approval Has appropriate ethics or institutional review approval been obtained, if required? \u2610 Yes \u2610 Pending \u2610 Not applicable Legal basis for data use Is there a clear and appropriate legal basis for the proposed data use? \u2610 Satisfactory \u2610 Needs clarification \u2610 Unsatisfactory Participant expectations Is the proposed use consistent with participant consent and reasonable expectations? \u2610 Satisfactory \u2610 Needs clarification \u2610 Unsatisfactory"},{"location":"DACrubric/#5-data-protection-and-security","title":"5. Data Protection and Security","text":"Criterion Assessment Considerations Rating Data handling plan Is there a clear plan for secure storage, access, and processing of data? \u2610 Satisfactory \u2610 Needs clarification \u2610 Unsatisfactory Risk of re-identification Are risks of re-identification assessed and mitigated? \u2610 Low \u2610 Moderate \u2610 High Data retention and destruction Are retention periods and disposal methods clearly defined? \u2610 Satisfactory \u2610 Needs clarification \u2610 Unsatisfactory"},{"location":"DACrubric/#6-data-use-sharing-and-outputs","title":"6. Data Use, Sharing, and Outputs","text":"Criterion Assessment Considerations Rating Intended analyses and outputs Are analyses and outputs clearly described and appropriate? \u2610 Satisfactory \u2610 Needs clarification \u2610 Unsatisfactory Restrictions on reuse Are secondary use, onward sharing, or commercial use appropriately addressed? \u2610 Satisfactory \u2610 Needs clarification \u2610 Unsatisfactory Acknowledgement and attribution Are plans for acknowledgement of the Registry and contributors specified? \u2610 Satisfactory \u2610 Needs clarification \u2610 Unsatisfactory"},{"location":"DACrubric/#7-conflicts-of-interest","title":"7. Conflicts of Interest","text":"Criterion Assessment Considerations Rating Declared conflicts Have all potential conflicts of interest been declared? \u2610 Yes \u2610 No Impact of conflicts Could any declared conflict compromise objectivity or trust? \u2610 Low \u2610 Moderate \u2610 High"},{"location":"DACrubric/#8-overall-assessment-and-decision","title":"8. Overall Assessment and Decision","text":""},{"location":"DACrubric/#summary-of-key-strengths","title":"Summary of Key Strengths","text":""},{"location":"DACrubric/#summary-of-key-concerns","title":"Summary of Key Concerns","text":""},{"location":"DACrubric/#dac-decision","title":"DAC Decision","text":"<ul> <li>\u2610 Approved</li> <li>\u2610 Approved with conditions</li> <li>\u2610 Not approved</li> </ul>"},{"location":"DACrubric/#conditions-or-recommendations-if-applicable","title":"Conditions or Recommendations (if applicable)","text":""},{"location":"DACrubric/#notes","title":"Notes","text":"<ul> <li>Requests involving high-risk or highly sensitive data may require additional   safeguards, restrictions, or staged access.</li> <li>The DAC may revisit decisions if project scope or data use changes.</li> </ul> <p>This rubric is provided as a template and may be adapted to fit the needs and maturity of different registries or data repositories.</p>"},{"location":"acknowledgements/","title":"Acknowledgements","text":"<p>Sample Content Only</p> <p>This page contains example language and placeholders designed to help registry teams build their own data sharing site. Please replace all placeholder text with details specific to your own project, policies, and governance requirements.</p>"},{"location":"acknowledgements/#we-gratefully-acknowledge-the-following-organizations-collaborators-and-contributors","title":"We gratefully acknowledge the following organizations, collaborators, and contributors:","text":""},{"location":"acknowledgements/#project-team","title":"\ud83e\uddd1\u200d\ud83d\udd2c Project Team","text":"<ul> <li>Dr. Danielle Boyce \u2013 Principal Investigator</li> <li>[Your Name Here] \u2013 Project Coordinator</li> <li>[Team Member Name] \u2013 Data Manager</li> </ul>"},{"location":"acknowledgements/#partner-institutions","title":"\ud83c\udfdb\ufe0f Partner Institutions","text":"<ul> <li>[Institution 1 Name]</li> <li>[Institution 2 Name]</li> <li>[Funding Agency Name, if applicable]</li> </ul>"},{"location":"acknowledgements/#funding-support","title":"\ud83d\udcb8 Funding Support","text":"<p>This work was supported by: - [Grant Name or Number] - [Institutional Support Description]</p>"},{"location":"acknowledgements/#collaborators","title":"\ud83e\udd1d Collaborators","text":"<p>We also thank the patient advocacy groups, clinicians, and researchers who have helped shape the design and use of this registry.</p> <p>This documentation template was created using MkDocs and the Material for MkDocs theme.</p>"},{"location":"cohort-overview/","title":"Descriptive Cohort Overview","text":"<p>\u26a0\ufe0f Sample Content Only This page includes placeholder language meant to help registry teams create their own cohort summary. Please replace all text and values with data specific to your project.</p>"},{"location":"cohort-overview/#purpose","title":"\ud83d\udd0d Purpose","text":"<p>This overview provides a high-level summary of the patient population currently included in the registry. It is intended to support researchers in assessing feasibility and relevance for proposed research.</p>"},{"location":"cohort-overview/#participant-summary","title":"\ud83d\udc65 Participant Summary","text":"<ul> <li>Total enrolled participants: [Insert number]</li> <li>Data collection start date: [Insert date]</li> <li>Most recent data freeze or refresh: [Insert date]</li> <li>Participating sites (if applicable): [List or number]</li> </ul>"},{"location":"cohort-overview/#key-demographics","title":"\ud83d\udcca Key Demographics","text":"Variable Summary Age (mean/range) [e.g., 47 years (range: 18\u201392)] Sex distribution [e.g., 58% female, 42% male] Race/Ethnicity [Insert summary or \"See table below\"] Geographic distribution [e.g., 12 U.S. states + 3 international sites]"},{"location":"cohort-overview/#clinical-highlights","title":"\ud83e\uddfe Clinical Highlights","text":"<p>Include a few registry-specific clinical characteristics here:</p> <ul> <li>Most common diagnoses: [e.g., Disease A (35%), Disease B (28%)]</li> <li>Treatment history recorded: [e.g., Yes \u2013 medications, surgeries, etc.]</li> <li>Key clinical variables: [e.g., biomarker values, diagnostic imaging, lab results]</li> </ul>"},{"location":"cohort-overview/#available-data-domains","title":"\ud83d\udcc2 Available Data Domains","text":"<p>The registry captures data in the following categories:</p> <ul> <li>Demographics</li> <li>Medical history</li> <li>Diagnostic test results</li> <li>Treatments and procedures</li> <li>Patient-reported outcomes</li> <li>[Other categories]</li> </ul> <p>For full variable definitions, see the Data Dictionary.</p>"},{"location":"cohort-overview/#additional-notes","title":"\ud83d\udcce Additional Notes","text":"<ul> <li>Data availability may vary across time periods and sites.</li> <li>Data extraction requires review and approval\u2014see Information for Researchers for details.</li> </ul>"},{"location":"cohort-overview/#contact","title":"\ud83d\udcec Contact","text":"<p>Questions? Contact [datarequests@yourorganization.org] for more information or to request a detailed data cut.</p> <p>Last updated: [Insert date] Note: This summary is provided for general awareness and planning purposes. It reflects a snapshot of the registry at the time of analysis and may not reflect current enrollment.</p>"},{"location":"customization/","title":"Data Sharing In A Box","text":"<p>Sample Content Only</p> <p>This site is a template with example content to help registry teams publish their data access documentation. Please review and customize every page before sharing this site publicly, especially sections about governance, IRB, and consent. Remove any placeholder files or references that do not apply to your project.</p>"},{"location":"customization/#how-to-set-up-and-use-the-patient-registry-template","title":"\u2600\ufe0f How to Set Up and Use the Patient Registry Template","text":"<p>This template helps patient registry teams or patient advocacy organizations create a transparent, accessible data sharing website. It\u2019s built using MkDocs with the Material theme.</p>"},{"location":"customization/#1-copy-this-template-repository","title":"1. Copy This Template Repository","text":"<p>You have two options:</p> <ul> <li>Use GitHub\u2019s \u201cUse this template\u201d button (recommended):</li> <li>Go to the template repository.</li> <li>Click \"Use this template\" to create your own copy.</li> <li>Name your new repository (e.g., <code>my-registry-docs</code>) and choose whether it will be public or private.</li> </ul>"},{"location":"customization/#screenshot","title":"Screenshot","text":"<ul> <li>Manual download:</li> <li>Download this repo as a ZIP and upload the contents to a new GitHub repo.</li> <li>Or use <code>git clone</code> and rename the folder.</li> </ul>"},{"location":"customization/#2-customize-your-site-metadata","title":"2. Customize Your Site Metadata","text":"<p>Open <code>mkdocs.yml</code> and update the following:</p> <ul> <li><code>site_name</code>: Name of your registry or data program.</li> <li><code>site_url</code>: Optional, for your published documentation URL.</li> <li><code>repo_url</code> / <code>repo_name</code>: To link back to your GitHub repo.</li> <li><code>logo:</code> and <code>favicon:</code> paths: Point to your own organization\u2019s branding under <code>assets/img/</code>.</li> </ul>"},{"location":"customization/#3-review-and-update-all-pages","title":"3. Review and Update All Pages","text":"<p>All Markdown content lives in the <code>docs/</code> folder. Use this checklist to customize the files:</p> File Customize This Content <code>index.md</code> Welcome message and registry overview <code>researchers.md</code> Data request process \u2014 revise for your workflow <code>survey.md</code> End-user intake survey \u2014 update to reflect your IRB/data needs <code>cohort-overview.md</code> Describe the population, enrollment, and structure of your data <code>data-dictionary.md</code> Your variable-level data documentation <code>derived-fields.md</code> Add any harmonized, derived, or computed variables <code>dua.md</code> Full or summary of your data use terms <code>irb.md</code> IRB protocol number, contact, or exemption justification <code>faq.md</code> Questions data users often ask <code>key_resources.md</code> Links to internal and external tools/policies <code>acknowledgements.md</code> People or groups who contributed to the data/registry <code>data-platforms.md</code> Tools or environments you support (e.g. enclaves, APIs) <code>data-readiness.md</code> A checklist for evaluating your registry\u2019s documentation before sharing <code>external-sharing.md</code> Considerations before joining data aggregation efforts (e.g. privacy, harmonization, governance alignment) <p>\ud83d\uddd1\ufe0f Remove or hide pages that aren\u2019t relevant to your registry:</p> <ul> <li>To delete: Remove the file in <code>docs/</code> and its entry in <code>mkdocs.yml</code></li> <li>To hide: Remove from <code>mkdocs.yml</code> only</li> <li>To rename: Rename both the file and its nav entry</li> </ul>"},{"location":"customization/#4-preview-your-site-locally-optional","title":"4. Preview Your Site Locally (Optional)","text":"<pre><code>pip install mkdocs mkdocs-material\nmkdocs serve\n</code></pre> <p>Then open <code>http://127.0.0.1:8000</code> in a browser to preview your site before publishing.</p>"},{"location":"customization/#5-publish-with-github-pages","title":"5. Publish with GitHub Pages","text":"<p>Once GitHub Pages is enabled:</p> <ol> <li>Push changes to <code>main</code>.</li> <li>GitHub Actions will build and publish your site automatically.</li> <li>In your repo settings, go to Settings &gt; Pages and confirm the site is deployed.</li> </ol>"},{"location":"customization/#pro-tips","title":"\u2705 Pro Tips","text":"<ul> <li>\ud83e\uddea Use the \u201cEnd User Survey\u201d to collect use-case info from data requestors</li> <li>\ud83d\udd10 Be clear about what\u2019s required before data access (DUA, IRB, etc.)</li> <li>\ud83d\udddd Use the \u201cExternal Sharing\u201d page to guide internal governance decisions</li> </ul>"},{"location":"customization/#license","title":"License","text":"<p>This template is provided under a CC BY 4.0 license. You may adapt it freely, but please credit the original source. Learn more</p>"},{"location":"data-dictionary/","title":"Data Dictionary","text":"<p>Sample Content Only</p> <p>This page contains example language and placeholders designed to help registry teams build their own data sharing site. Please replace all placeholder text with details specific to your own project, policies, and governance requirements.</p>"},{"location":"data-dictionary/#data-dictionary","title":"Data Dictionary","text":"<p>This page provides a detailed data dictionary for the registry. Below is a list of the key data fields collected, along with their definitions and allowable values. Use this as a reference to understand the data set.</p> Field Name Description Type / Units Notes <code>patient_id</code> Unique identifier for each patient Integer (e.g., study ID, no personal info) <code>enrollment_date</code> Date the patient was enrolled in the registry Date (YYYY-MM-DD) <code>age_at_enrollment</code> Age of patient at time of enrollment Integer (years) Derived from DOB and enrollment date ...add your fields... <p>Instructions: Edit the table above to include all variables in your data set. For each field, provide a clear description. Include units or format (e.g., \"Date (YYYY-MM-DD)\" or \"Categorical: 0=No, 1=Yes\"), and any notes (like derivation or if the field is optional). If your registry has multiple tables or modules of data, you could split this into multiple pages or sections.</p>"},{"location":"data-platforms/","title":"Choosing a Secure Storage Platform for Shared Registry Data","text":"<p>Patient registry teams must carefully consider where and how to store and share data, particularly when sharing with external researchers. The platform used should support regulatory compliance, data privacy, secure access, scalability, and usability across technical skill levels. Below is a breakdown of key storage and access models, major cloud vendors, and important considerations for implementation.</p>"},{"location":"data-platforms/#data-hosting-options","title":"\ud83d\udd10 Data Hosting Options","text":""},{"location":"data-platforms/#1-cloud-based-platforms","title":"1. Cloud-Based Platforms","text":"<ul> <li>Amazon Web Services (AWS)</li> <li>HIPAA-eligible services (e.g., S3, RDS, EC2)</li> <li>Supports secure data lakes, analytics, and machine learning</li> <li>Common choice for enterprise health data infrastructure</li> <li> <p>Broad integration with Python/R/SQL-based notebooks (e.g., SageMaker, EMR)</p> </li> <li> <p>Microsoft Azure</p> </li> <li>Trusted by many academic medical centers</li> <li>Tools for AI/ML, relational databases, and Azure Synapse Analytics</li> <li> <p>Provides granular identity and access control</p> </li> <li> <p>Google Cloud Platform (GCP)</p> </li> <li>Popular in research computing (BigQuery, Cloud Datalab)</li> <li>Optimized for analytics-heavy workflows</li> <li>Strong support for FHIR and healthcare APIs</li> </ul>"},{"location":"data-platforms/#2-localinstitutional-servers","title":"2. Local/Institutional Servers","text":"<ul> <li>Maintained by your own organization (e.g., hospital IT, university research computing)</li> <li>May be required by data governance agreements</li> <li>Pros: direct control, no third-party exposure</li> <li>Cons: scaling, security patching, and external access can be more difficult</li> </ul>"},{"location":"data-platforms/#key-questions-to-ask","title":"\ud83d\udd0d Key Questions to Ask","text":"<ul> <li>Does the platform meet HIPAA, GDPR, or IRB requirements?</li> <li>What data access controls are supported (e.g., single sign-on, user audit logs)?</li> <li>Are there approved environments for PHI or limited data sets?</li> <li>What types of users will need access (e.g., R users, Python users, Stata/SPSS users)?</li> <li>Will external collaborators work within a secure enclave or receive downloaded datasets?</li> </ul>"},{"location":"data-platforms/#enclave-environments-an-alternative-to-downloading-data","title":"\ud83d\udca1 Enclave Environments: An Alternative to Downloading Data","text":"<p>Instead of providing datasets for download, some registries use a secure enclave\u2014a virtual environment where researchers log in to conduct analyses remotely. These setups often use Jupyter Notebooks, RStudio Server, or even locked-down terminal access. </p>"},{"location":"data-platforms/#benefits","title":"Benefits","text":"<ul> <li>Enhanced security: no raw data leaves the enclave</li> <li>Audit logs and reproducibility</li> <li>Easier to control software, packages, and compute environments</li> </ul>"},{"location":"data-platforms/#limitations-and-considerations","title":"Limitations and Considerations","text":"<ul> <li>Users must adapt to cloud-based workflows (e.g., notebooks)</li> <li>Some researchers prefer point-and-click tools (e.g., SPSS/Stata)</li> <li>Requires robust user support and onboarding</li> <li>Data visualization may be limited unless tools are configured</li> </ul>"},{"location":"data-platforms/#examples-of-enclave-tools","title":"Examples of Enclave Tools","text":"<ul> <li>AWS SageMaker Studio Lab / EC2 JupyterHub</li> <li>Microsoft Azure Machine Learning Workspaces</li> <li>GCP Vertex AI Workbench</li> <li>NIH's BioData Catalyst / dbGaP Authorized Access Workspaces</li> </ul>"},{"location":"data-platforms/#summary-match-tools-to-users","title":"\ud83d\udd04 Summary: Match Tools to Users","text":"Feature/Need Best Fit Platform Raw statistical file sharing Encrypted cloud folder or secure FTP SQL analysis and reporting Cloud-hosted RDS or BigQuery Notebook-based collaboration AWS/GCP/Azure Notebooks or JupyterHub Protected health information Enclave with IRB + DUA controls <p>When in doubt, start with a small pilot and gather user feedback before expanding access.</p> <p>For policy implications and best practices, see the NIH Data Sharing Language Explained section.</p>"},{"location":"data-readiness/","title":"Data Sharing Readiness Assessment","text":"<p>Purpose of This Checklist</p> <p>This page helps registry holders, patient advocacy groups, and data stewards assess their data sharing readiness including documentation, governance, technical infrastructure, and data standardization.</p> <p>It is especially useful for registries that include multiple data sources (e.g., EHR, surveys, biosamples, imaging, genomics) and want to prepare for external data sharing, harmonization, or OMOP mapping.</p>"},{"location":"data-readiness/#how-to-use-this-page","title":"\ud83e\udded How to Use This Page","text":"<p>This assessment is organized into three layers:</p> <ol> <li>Foundational Readiness: Can your data be responsibly shared?</li> <li>Standardization Readiness: Can others understand and reuse it?</li> <li>OMOP Readiness (Optional): Can it be transformed into a common data model?</li> </ol> <p>You do not need to complete every section to begin sharing data. Use what fits your use case/goals.</p>"},{"location":"data-readiness/#layer-1-foundational-data-sharing-readiness","title":"\ud83e\uddf1 Layer 1: Foundational Data Sharing Readiness","text":""},{"location":"data-readiness/#1-registry-content-inventory","title":"\ud83e\uddfe 1. Registry Content Inventory","text":"<ul> <li> Master variable list compiled across all data sources  </li> <li> Data Dictionary exists for each data set (surveys, labs, genomics, etc.)  </li> <li> Linkage documentation describes how sources are joined (e.g., participant ID, visit date)  </li> <li> Data source tags included for merged variables (provenance)  </li> <li> Derived variables clearly labeled with source(s) documented  </li> <li> Date standardization and time alignment addressed  </li> <li> Missingness summary reported per source  </li> <li> Cohort definition consistent across sources  </li> </ul>"},{"location":"data-readiness/#2-governance-documentation","title":"\ud83d\udcc4 2. Governance &amp; Documentation","text":"<ul> <li> Data Use Agreement (DUA) specifies which data sources are shared  </li> <li> IRB protocol covers all data sets and secondary use  </li> <li> Consent language reviewed for each source (EHR, biospecimen, survey)  </li> <li> Oversight committee includes data set-specific expertise  </li> <li> Review process supports partial or multi-source requests  </li> <li> End-user intake form asks which data types are requested  </li> <li> Publications policy supports tiered or layered access  </li> </ul>"},{"location":"data-readiness/#3-technical-infrastructure","title":"\ud83d\udcbb 3. Technical Infrastructure","text":"<ul> <li> Each data source available in a common export format (CSV, RDS, JSON, etc.)  </li> <li> Data integration pipeline documented (manual or automated)  </li> <li> De-identified linking key exists  </li> <li> Secure transfer options for large or sensitive files  </li> <li> Remote analysis environment available if needed  </li> <li> Access logs / audit trails maintained  </li> <li> Documentation portal or metadata catalog exists  </li> </ul>"},{"location":"data-readiness/#4-registry-team-roles-capacity","title":"\ud83d\udc65 4. Registry Team Roles &amp; Capacity","text":"<ul> <li> Staff assigned per source (e.g., genomics lead, EHR analyst)  </li> <li> Request fulfillment timelines defined  </li> <li> Capacity to answer provenance and transformation questions  </li> <li> Governance team understands cross-source dependencies  </li> </ul>"},{"location":"data-readiness/#5-privacy-and-ethics","title":"\ud83d\udd10 5. Privacy and Ethics","text":"<ul> <li> Identifiability risk assessed across combined data sets  </li> <li> Omics, imaging, geospatial data reviewed for re-identification risk  </li> <li> HIPAA / GDPR compliance validated per data stream  </li> <li> Tiered access model defined (public, controlled, restricted)  </li> <li> Secure analysis options offered for sensitive data  </li> <li> Data destruction policy covers all formats and systems  </li> </ul>"},{"location":"data-readiness/#layer-2-data-standardization-readiness-recommended","title":"\ud83e\udde9 Layer 2: Data Standardization Readiness (Recommended)","text":"<p>Why is this important?</p> <p>Even well-governed data can be hard to reuse if variables, codes, and meanings are inconsistent. This section helps assess semantic readiness for harmonization across registries or studies.</p>"},{"location":"data-readiness/#6-variable-definitions-semantics","title":"\ud83e\udde0 6. Variable Definitions &amp; Semantics","text":"<ul> <li> Variables have clear, unambiguous definitions </li> <li> Similar variables across sources are reconciled  </li> <li> Units stored separately and consistently  </li> <li> Dates distinguish onset vs diagnosis vs observation </li> <li> Null values distinguish missing, unknown, and not applicable </li> </ul>"},{"location":"data-readiness/#7-standard-vocabulary-use","title":"\ud83e\uddec 7. Standard Vocabulary Use","text":"<ul> <li> Diagnoses coded or mappable (SNOMED, ORPHA, MONDO)  </li> <li> Phenotypes structured or mappable (HPO)  </li> <li> Labs coded or mappable (LOINC + UCUM units)  </li> <li> Medications normalized (RxNorm / ATC)  </li> <li> Procedures use a recognized coding system  </li> <li> Source values retained alongside standard codes  </li> </ul>"},{"location":"data-readiness/#8-data-quality-provenance","title":"\ud83d\udcca 8. Data Quality &amp; Provenance","text":"<ul> <li> Completeness monitored by source  </li> <li> Value range and format checks defined  </li> <li> Provenance captured for merged variables  </li> <li> data set versions tracked with change logs  </li> </ul>"},{"location":"data-readiness/#layer-3-omop-readiness","title":"\ud83e\uddec Layer 3: OMOP Readiness","text":"<p>Optional but Powerful</p> <p>Complete this section if you plan to:</p> <ul> <li>Participate in federated networks  </li> <li>Enable multi-registry analytics  </li> <li>Support reproducible, model-driven research  </li> </ul>"},{"location":"data-readiness/#9-omop-structural-fit","title":"\ud83e\uddf1 9. OMOP Structural Fit","text":"<ul> <li> Person-level records with stable IDs  </li> <li> Visit or event-based structure  </li> <li> Longitudinal data capture  </li> <li> Core clinical domains represented  </li> </ul> OMOP Domain Present PERSON \u2b1c VISIT_OCCURRENCE / DETAIL \u2b1c CONDITION_OCCURRENCE \u2b1c MEASUREMENT \u2b1c DRUG_EXPOSURE \u2b1c PROCEDURE_OCCURRENCE \u2b1c OBSERVATION \u2b1c DEATH \u2b1c"},{"location":"data-readiness/#10-omop-etl-practicality","title":"\ud83d\udd04 10. OMOP ETL Practicality","text":"<ul> <li> Source tables are stable  </li> <li> Variable meanings are consistent  </li> <li> Units explicitly stored  </li> <li> Dates are parseable and complete  </li> <li> Corrections and updates can be tracked  </li> </ul>"},{"location":"data-readiness/#omop-readiness-scale-rubric","title":"\ud83d\udcd0 OMOP Readiness Scale &amp; Rubric","text":"<p>What This Scale Is For</p> <p>This rubric helps registries understand how close they are to OMOP Common Data Model (CDM) adoption, and what steps are needed to move forward.</p> <p>OMOP readiness is not all-or-nothing. Many registries progress through these levels over time.</p>"},{"location":"data-readiness/#omop-readiness-levels-04","title":"\ud83d\udea6 OMOP Readiness Levels (0\u20134)","text":""},{"location":"data-readiness/#level-0-not-omop-ready","title":"Level 0: Not OMOP-Ready","text":"<p>Status: Foundational gaps prevent OMOP mapping.</p> <p>Typical characteristics - No stable person identifiers - Flat or cross-sectional data only - Heavy reliance on free text for key domains - No consistent visit or event dates - Variable definitions unclear or missing  </p> <p>What to focus on next - Create a master data dictionary - Define person- and event-level structure - Standardize dates, identifiers, and provenance  </p>"},{"location":"data-readiness/#level-1-structurally-aware","title":"Level 1: Structurally Aware","text":"<p>Status: Data structure exists, but semantics are weak.</p> <p>Typical characteristics - Person-level records with stable IDs - Longitudinal data present - Minimal or inconsistent use of standard vocabularies - Local codes or free text dominate - Mapping would rely heavily on OMOP <code>OBSERVATION</code> </p> <p>What to focus on next - Clarify variable definitions - Identify candidate standard vocabularies - Normalize units and dates  </p>"},{"location":"data-readiness/#level-2-terminology-mappable","title":"Level 2: Terminology Mappable","text":"<p>Status: Core domains can be mapped with moderate effort.</p> <p>Typical characteristics - Diagnoses, labs, and medications partially coded or mappable - Units stored separately - Source values preserved - Visit structure mostly consistent - Limited governance around vocabularies  </p> <p>What to focus on next - Formalize vocabulary mappings - Reduce free text in high-value fields - Document mapping decisions  </p>"},{"location":"data-readiness/#level-3-omop-compatible","title":"Level 3: OMOP-Compatible","text":"<p>Status: OMOP ETL feasible with standard effort.</p> <p>Typical characteristics - Core clinical domains map cleanly to OMOP tables - Standard vocabularies used consistently - Longitudinal visits or events well-defined - Provenance and versioning tracked - Initial OMOP ETL completed or piloted  </p> <p>What to focus on next - Expand to additional domains (e.g., genomics, PROs) - Improve automation and quality assurance - Prepare for federated analyses  </p>"},{"location":"data-readiness/#level-4-omop-operational","title":"Level 4: OMOP-Operational","text":"<p>Status: OMOP is production-ready and reusable.</p> <p>Typical characteristics - Routine OMOP refreshes - Automated and versioned ETL pipeline - Data quality checks aligned with OMOP conventions - Participation in federated or networked studies - Clear governance for mappings and updates  </p> <p>What to focus on next - Optimization and performance - Advanced phenotyping and cohort reuse - Cross-network harmonization  </p>"},{"location":"data-readiness/#how-to-assign-a-level","title":"\ud83d\udcca How to Assign a Level","text":"<p>Use the OMOP checklists above and apply the following rule:</p> <ul> <li>Level 0: Fails multiple Structural Fit items  </li> <li>Level 1: Structural Fit \u2714, Terminology Mapping mostly \u2716  </li> <li>Level 2: Structural Fit \u2714, Terminology Mapping mostly \u2714  </li> <li>Level 3: Structural + Terminology + ETL Practicality \u2714  </li> <li>Level 4: Level 3 plus operationalized ETL and reuse  </li> </ul>"},{"location":"data-readiness/#optional-quantitative-scoring","title":"\ud83e\uddee Optional Quantitative Scoring","text":"<p>Assign points to each OMOP readiness checklist item:</p> <ul> <li>\u2714 = 1 point  </li> <li>\u2716 = 0 points  </li> </ul> <p>Score ranges - 0\u20134: Level 0 - 5\u20138: Level 1 - 9\u201312: Level 2 - 13\u201316: Level 3 - 17+: Level 4  </p>"},{"location":"data-readiness/#tips-for-multi-source-registries","title":"\ud83e\udde9 Tips for Multi-Source Registries","text":"<ul> <li>Use data source tagging and consistent naming conventions  </li> <li>Track data provenance: what came from where, and when  </li> <li>Clarify which data sources are required vs optional </li> <li>Share core data sets by default, restrict sensitive or high-dimensional data  </li> <li>Provide diagrams of data architecture or flow </li> </ul>"},{"location":"data-readiness/#summary","title":"\ud83d\udccc Summary","text":"<p>Use this assessment to identify gaps before inviting data access requests or pursuing harmonization.</p> <p>Many registries begin with Layer 1, progress through Layer 2, and only complete Layer 3 when needed.</p> <p>Consider publishing a data inventory table summarizing each source, access level, and documentation status.</p> <p>Need help? Visit the How to Customize This Template page or contact your data governance advisor.</p>"},{"location":"derived-fields/","title":"Derived Fields","text":"<p>Sample Content Only</p> <p>This page contains example language and placeholders designed to help registry teams build their own data sharing site. Please replace all placeholder text with details specific to your own project, policies, and governance requirements.</p>"},{"location":"derived-fields/#derived-fields-documentation","title":"Derived Fields Documentation","text":"<p>This page explains any derived or calculated fields in the registry data set. Derived fields are those not collected directly, but computed from other data. Documenting them is important for transparency and reproducibility.</p> <p>For each derived variable, explain how it\u2019s calculated or defined. For example:</p> <ul> <li>Body Mass Index (BMI): Calculated as weight (kg) divided by squared height (m^2), using the most recent weight and height from the patient record.</li> <li>Age Group: Derived from the exact age; categorized into groups (0-17 = child, 18-64 = adult, 65+ = senior) at time of enrollment.</li> <li>Disease Duration: Computed as the time in years from reported diagnosis date to the last follow-up date.</li> </ul> <p>Instructions: Replace the examples with your actual derived fields. Provide enough detail that another researcher could recreate the field from the source data. If a derived field comes from an external algorithm or reference, cite or describe that as well.</p>"},{"location":"dua/","title":"Data Use Agreement","text":"<p>Sample Content Only</p> <p>This page includes sample terms and procedures adapted from other registries. Please update all placeholders and ensure your local legal and governance teams review your final version.</p>"},{"location":"dua/#data-use-agreement-dua-research-data-access","title":"Data Use Agreement (DUA) &amp; Research Data Access","text":"<p>This page outlines the procedures and terms for requesting access to data from the [Registry Name], maintained by [Registry Organization]. These policies are designed to ensure secure and ethical use of patient-level registry data.</p>"},{"location":"dua/#how-to-request-data","title":"\ud83d\udd11 How to Request Data","text":"<p>All data requests must include:</p> <ul> <li>A completed data request form (linked or attached by your registry)</li> <li>Proof of IRB submission or approval</li> <li>A signed Confidentiality Agreement (template available upon request)</li> <li>A detailed list of requested variables or data domains</li> </ul> <p>To initiate a request, contact [datarequests@yourorganization.org] or visit our Data Request Portal.</p> <p>\ud83d\udd50 Standard review time is 3\u20136 months depending on complexity.</p> <p>\ud83d\udca1 Note: Industry or commercial requests may follow a separate process. Contact [industryrequests@yourorganization.org] for more information.</p>"},{"location":"dua/#terms-and-conditions","title":"\ud83d\udd12 Terms and Conditions","text":"<p>Access is contingent upon full compliance with these data use requirements:</p> <ul> <li>Only non-identifiable data will be shared unless approved under a Limited Data Set with additional agreements.</li> <li>The dataset may only be used for the specific project outlined in your application.</li> <li>No attempts to re-identify participants are permitted.</li> <li>Data must be stored securely and may not be redistributed.</li> <li>Investigators must submit abstracts 7 days and manuscripts 30 days prior to submission for registry review.</li> <li>Projects must be completed within 3 years of data access; extensions may be requested.</li> <li>Upon study completion, all data files must be destroyed and written confirmation sent to the registry.</li> </ul> <p>\ud83d\udcdd Suggested Acknowledgment Language:  </p> <p>\u201cThe authors thank [Registry Organization] for providing access to [Registry Name] data for this study. We extend our gratitude to the individuals who contributed data and the participating sites.\u201d</p> <p>\ud83d\udce2 Suggested Data Availability Statement:  </p> <p>\u201cData are available upon reasonable request through the [Registry Organization]'s Research Oversight Committee. Contact [datarequests@yourorg.org] for details. Access restrictions apply to protect patient privacy.\u201d</p>"},{"location":"dua/#signature-requirements","title":"\ud83d\udcc4 Signature Requirements","text":"<p>The following must be signed and submitted:</p> <ul> <li>Confidentiality Agreement</li> <li>(If applicable) Information Use Agreement (IUA) for Limited Data Sets</li> <li>IRB approval letter</li> </ul> <p>The Principal Investigator (PI) must be affiliated with the institution responsible for data analysis. Changes in personnel or institution must be reported to [Registry Organization].</p>"},{"location":"dua/#citation","title":"Citation","text":"<p>Adapted with permission from the Cystic Fibrosis Foundation: CFFPR Data Application and Confidentiality Agreement.</p>"},{"location":"external-repository/","title":"Sharing Data with External Repositories: Considerations for Patient Registry Owners","text":"<p>Purpose of This Checklist</p> <p>This page helps registry holders or patient advocacy groups assess their data sharing readiness when considering participation in external data aggregation initiatives. It is especially useful for all registries including those with multiple data types and sources (e.g., EHR, surveys, biosamples, imaging, omics) and supports discussions around data governance, privacy, technical formats, and alignment with organizational values.</p> <p>Sharing data from a patient registry with external data repositories or aggregators can greatly amplify the impact of those data, but it requires careful planning and governance. This guidance is intended for all stakeholders involved in a registry \u2013 technical leads, program managers, and governance staff alike \u2013 and covers benefits, legal/ethical considerations, data formatting and harmonization, privacy concerns, long-term stewardship, and emerging models (like federated networks and the OMOP common data model). These considerations apply across data types (clinical data, genomic data, patient-reported outcomes, etc.).</p>"},{"location":"external-repository/#benefits-of-participating-in-external-data-platforms","title":"Benefits of Participating in External Data Platforms","text":"<ul> <li>Accelerate research and insights, particularly for rare diseases or small populations</li> <li>Gain access to advanced analytics and domain expertise</li> <li>Increase visibility and impact through collaboration and broader dissemination</li> <li>Support public health and drug development via real-world data</li> </ul>"},{"location":"external-repository/#governance-ethical-and-legal-considerations","title":"Governance, Ethical, and Legal Considerations","text":"<ul> <li>Data Ownership and Rights: Confirm your ability to share and retain control where needed.</li> <li>Participant Consent and IRB: Ensure data sharing aligns with consents and ethical approvals.</li> <li>Data Sharing Agreements: Use formal contracts to govern use, access, and attribution.</li> <li>Oversight: Establish a Data Access Committee and transparent approval processes.</li> <li>Regulatory Compliance: Align with HIPAA, GDPR, and other privacy regulations.</li> </ul> <p>Key Questions:</p> <ol> <li>Who owns and controls the data post-sharing?</li> <li>What is allowed under the data sharing agreement?</li> <li>How is privacy protected?</li> <li>What oversight does the registry retain?</li> <li>What are the costs and resource needs?</li> </ol>"},{"location":"external-repository/#data-formatting-and-harmonization","title":"Data Formatting and Harmonization","text":"<ul> <li>Common Data Models: Adopt standards like OMOP for interoperability.</li> <li>Terminologies and Ontologies: Use controlled vocabularies (e.g., SNOMED CT, LOINC).</li> <li>Metadata and Documentation: Provide data dictionaries and provenance details.</li> <li>Curation Support: Coordinate with repositories on standardization and validation.</li> </ul>"},{"location":"external-repository/#privacy-and-security-considerations","title":"Privacy and Security Considerations","text":"<ul> <li>De-identification: Remove direct/indirect identifiers per HIPAA and GDPR.</li> <li>Sensitive Data: Treat genomics and biomarker data with extra caution.</li> <li>Security Standards: Ensure encrypted storage, secure transfers, and role-based access.</li> <li>Transparency: Communicate plans to participants and oversight boards.</li> </ul>"},{"location":"external-repository/#long-term-data-stewardship","title":"Long-Term Data Stewardship","text":"<ul> <li>Retention: Understand repository policies for long-term storage and sunsetting.</li> <li>Versioning: Plan for data updates and user notifications.</li> <li>Monitoring Use: Track and report on downstream data access and use.</li> <li>Revocation and Misuse: Have plans for removing or correcting data if needed.</li> <li>Attribution: Ensure acknowledgment policies are in place.</li> </ul>"},{"location":"external-repository/#federated-data-sharing-models","title":"Federated Data Sharing Models","text":"<ul> <li>Definition: Keep data local, share queries and aggregated results only.</li> <li>Advantages: Enhanced privacy, local control, compliance.</li> <li>Infrastructure: Requires standardization and compatible software.</li> <li>Use Cases: Ideal for cross-jurisdiction collaboration or high-sensitivity data.</li> </ul>"},{"location":"external-repository/#data-types-to-consider","title":"Data Types to Consider","text":"<ul> <li>Clinical Data: Standardized structured data (e.g., labs, medications)</li> <li>Genomics/Biomarkers: Consider file types, repositories, and privacy</li> <li>Patient-Reported Outcomes: Include instruments and scoring guides</li> <li>Biospecimens: Share metadata and access conditions</li> <li>Derived Variables: Explain algorithms and usage contexts</li> </ul>"},{"location":"external-repository/#summary","title":"Summary","text":"<p>Treat external data sharing as a strategic endeavor. With governance, technical preparation, and transparent policies, patient registries can responsibly amplify the utility of their data and accelerate research. Consider the guidance above a roadmap for initiating or refining your data sharing strategy.</p>"},{"location":"faq/","title":"FAQ","text":"<p>Sample Content Only</p> <p>This page contains example language and placeholders designed to help registry teams build their own data sharing site. Please replace all placeholder text with details specific to your own project, policies, and governance requirements.</p>"},{"location":"faq/#frequently-asked-questions-faq","title":"Frequently Asked Questions (FAQ)","text":""},{"location":"faq/#what-is-this-website","title":"\ud83d\udccc What is this website?","text":"<p>This site provides documentation for a patient registry project. It includes information on the data dictionary, governance, how to access the data, and more.</p>"},{"location":"faq/#who-can-request-access-to-the-data","title":"\ud83d\udcdd Who can request access to the data?","text":"<p>Access policies vary by registry. Please refer to the Data Access page for current eligibility and procedures.</p>"},{"location":"faq/#are-the-data-de-identified","title":"\ud83d\udd12 Are the data de-identified?","text":"<p>Yes. All data shared through this registry is de-identified according to HIPAA standards (or applicable regulations in your region).</p>"},{"location":"faq/#how-long-does-it-take-to-get-access","title":"\u23f3 How long does it take to get access?","text":"<p>Once a data use request is submitted with the required approvals, typical turnaround is 2\u20134 weeks.</p>"},{"location":"faq/#what-documents-are-required-to-request-data","title":"\ud83d\udcc3 What documents are required to request data?","text":"<p>Usually: - Completed Data Use Agreement (DUA) - IRB or ethics approval documentation - A brief proposal or justification for data use</p> <p>See the DUA and IRB pages for more information.</p>"},{"location":"faq/#can-i-link-this-data-with-other-data-sets","title":"\ud83e\udde9 Can I link this data with other data sets?","text":"<p>This depends on the registry\u2019s policies and the identifiers available. Please contact the data custodians for guidance.</p>"},{"location":"faq/#who-do-i-contact-with-other-questions","title":"\ud83d\udcec Who do I contact with other questions?","text":"<p>Email us at your.email@institution.edu or use the contact form on the homepage.</p>"},{"location":"industry/","title":"Guidance for Sharing App or Registry Data with Clinical Trial Sponsors","text":"<p>Disclaimer</p> <p>This document provides general guidance and is not legal advice. Legal, regulatory, and ethics experts should be consulted before implementing data-sharing practices.</p>"},{"location":"industry/#1-purpose","title":"1. Purpose","text":"<p>This document establishes a policy for the responsible sharing of patient-generated data (PGD) collected through a patient advocacy group's tracker application or patient registry. It is intended to protect:</p> <ul> <li>Clinical trial integrity</li> <li>Patient privacy and informed consent</li> <li>Ethical and regulatory compliance</li> <li>Scientific credibility</li> </ul>"},{"location":"industry/#2-scope","title":"2. Scope","text":"<p>This policy applies to:</p> <ul> <li>The patient tracker app or registry operated by the advocacy group</li> <li>Any biopharmaceutical company (\u201cSponsor\u201d), including those:<ul> <li>Conducting ongoing clinical trials</li> <li>Planning future trials</li> </ul> </li> </ul> <p>It governs sharing of:</p> <ul> <li>Aggregate and individual-level data</li> <li>Historical and contemporaneous datasets</li> <li>Scientific, commercial, and regulatory uses of patient-generated data</li> </ul>"},{"location":"industry/#3-regulatory-background-key-guidance","title":"3. Regulatory Background: Key Guidance","text":"<p>This section summarizes official FDA and EMA guidance, and concrete regulatory precedents, that are relevant to sharing patient-generated data (PGD) with clinical trial sponsors.</p>"},{"location":"industry/#31-fda-real-world-data-and-real-world-evidence-2023","title":"3.1 FDA \u2013 Real-World Data and Real-World Evidence (2023)","text":"<p>Guidance: \u201cConsiderations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products\u201d (Guidance for Industry, Aug 2023).</p> <ul> <li>FDA guidance</li> </ul> <p>Key points and quotes:</p> <ul> <li> <p>Sponsors are expected to have a prospectively defined protocol and SAP for any RWD study that will support a marketing application.</p> </li> <li> <p>The guidance states:  </p> <p>\u201cSponsors should provide draft versions of their proposed protocol and statistical analysis plan (SAP) for Agency review and comment\u2026\u201d</p> </li> <li> <p>FDA emphasizes that it must be confident that data sources and analyses were not selected to favor a particular conclusion. This is why informal, ad hoc use of external data streams is viewed skeptically.</p> </li> </ul>"},{"location":"industry/#32-fda-real-world-data-assessing-registries-dec-2023","title":"3.2 FDA \u2013 Real-World Data: Assessing Registries (Dec 2023)","text":"<p>Guidance: \u201cReal-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products\u201d (Guidance for Industry, Dec 2023).</p> <ul> <li>FDA guidance</li> </ul> <p>Key points and quotes:</p> <ul> <li> <p>Registries are defined as systems that enroll a predefined population and collect prespecified health-related data.</p> </li> <li> <p>The guidance notes:  </p> <p>\u201cEstablishing registries involves enrolling a predefined population and collecting prespecified health-related data for each patient in that population.\u201d</p> </li> <li> <p>For regulatory use, sponsors are responsible for ensuring the registry supports relevant and reliable data.</p> </li> <li> <p>The guidance also states:  </p> <p>\u201cSponsors should\u2026 submit the protocols and statistical analysis plans to the Agency before conducting the study.\u201d</p> </li> </ul> <p>Together, these guidance documents establish that regulatory-grade RWD/RWE must be pre-planned, protocol-driven, and governed, not ad hoc.</p>"},{"location":"industry/#33-ema-computerised-systems-and-electronic-data-in-clinical-trials-2023","title":"3.3 EMA \u2013 Computerised Systems and Electronic Data in Clinical Trials (2023)","text":"<p>Guideline: \u201cGuideline on Computerised Systems and Electronic Data in Clinical Trials\u201d (EMA/INS/GCP/112288/2023).</p> <ul> <li>EMA Guideline</li> </ul> <p>Key points and quotes:</p> <ul> <li> <p>The guideline sets expectations for validated, controlled computerised systems used for trial data, including ePRO, wearables, EHR, and other electronic sources.</p> </li> <li> <p>It explains that it:  </p> <p>\u201c\u2026covers requirements and expectations for computerised systems, including validation, user management, security, and electronic data for the data life cycle.\u201d</p> </li> <li> <p>The underlying goal is that all clinical-trial data used in decision-making are traceable, auditable and under sponsor or investigator control.</p> </li> </ul> <p>Unplanned importing of external app data into a trial context sits uncomfortably with these expectations.</p>"},{"location":"industry/#36-implication-for-patient-advocacy-group","title":"3.6 Implication for Patient-Advocacy Group","text":"<p>These guidance documents and precedents collectively support the view that:</p> <ul> <li>Non-prospectively-defined access to external data (such as contemporaneous patient-tracker data) is not aligned with regulatory expectations.</li> <li>Regulators expect RWD used in decisions to be gathered under pre-specified protocols and SAPs, in validated, controlled systems, and free from ad hoc \u201cdata peeking.\u201d</li> <li>Even if the sponsor does not intend to use the tracker data directly in a submission, access to such data can still create concerns about biasing trial conduct or interpretation.</li> </ul>"},{"location":"industry/#4-key-principles","title":"4. Key Principles","text":""},{"location":"industry/#41-prospective-planning","title":"4.1 Prospective Planning","text":"<p>All data sources and intended uses must be predefined. Non-prospectively planned data sharing is discouraged.</p>"},{"location":"industry/#42-protection-of-clinical-trial-integrity","title":"4.2 Protection of Clinical Trial Integrity","text":"<p>PGD must not:</p> <ul> <li>Unblind or risk unblinding</li> <li>Provide informal interim signals</li> <li>Influence trial conduct</li> <li>Circumvent DSMB/IDMC processes</li> </ul>"},{"location":"industry/#43-consent-privacy","title":"4.3 Consent &amp; Privacy","text":"<ul> <li>Sharing must align with the tracker app\u2019s consent</li> <li>De-identification must meet relevant regulatory standards</li> <li>Re-identification risk must be assessed</li> </ul>"},{"location":"industry/#44-data-governance","title":"4.4 Data Governance","text":"<p>Requires:</p> <ul> <li>A Data Use Agreement (DUA)</li> <li>Documented sponsor firewalls</li> </ul>"},{"location":"industry/#45-transparency","title":"4.5 Transparency","text":"<p>Patients should understand potential data-sharing practices.</p>"},{"location":"industry/#5-when-data-sharing-is-permissible","title":"5. When Data Sharing Is Permissible","text":""},{"location":"industry/#51-de-identified-or-anonymized-data","title":"5.1 De-Identified or Anonymized Data","text":"<ul> <li>Meets HIPAA/GDPR standards</li> <li>Re-identification risk assessed</li> </ul>"},{"location":"industry/#52-limited-impact-on-trials","title":"5.2 Limited Impact on Trials","text":"<ul> <li>Historical (non-contemporaneous)</li> <li>Aggregated</li> <li>Cannot reveal efficacy or safety trends</li> </ul>"},{"location":"industry/#53-governance-and-firewalls","title":"5.3 Governance and Firewalls","text":"<ul> <li>DUA in place</li> <li>Access limited to RWE teams</li> <li>Trial teams excluded</li> </ul>"},{"location":"industry/#54-clear-pre-specified-use","title":"5.4 Clear, Pre-Specified Use","text":"<p>Examples:</p> <ul> <li>Natural history studies</li> <li>Burden-of-illness projects</li> <li>HEOR</li> <li>Non-regulatory scientific uses</li> </ul>"},{"location":"industry/#55-ethics-oversight","title":"5.5 Ethics Oversight","text":"<p>Recommended for small rare-disease populations.</p>"},{"location":"industry/#6-when-data-sharing-is-not-permissible","title":"6. When Data Sharing Is Not Permissible","text":"<p>High-risk scenarios:</p> <ul> <li>Contemporaneous patient-level symptom data</li> <li>Data revealing efficacy/safety trends</li> <li>Likely overlap with trial participants</li> <li>Inadequate consent</li> <li>No DUA or governance</li> <li>Ad hoc exploratory sponsor requests</li> <li>Any sharing that could bias trial conduct</li> </ul> <p>Important: The issue exists even if the sponsor does not intend to use the data in a regulatory submission. Regulators assess whether access could have influenced the trial.</p>"},{"location":"industry/#7-operational-safeguards","title":"7. Operational Safeguards","text":""},{"location":"industry/#71-data-preparation","title":"7.1 Data Preparation","text":"<ul> <li>Predetermined data fields</li> <li>De-identified</li> <li>Aggregated</li> </ul>"},{"location":"industry/#72-timing-controls","title":"7.2 Timing Controls","text":"<ul> <li>Lag of \u22653\u20136 months</li> <li>Avoid sharing during blinded phases</li> </ul>"},{"location":"industry/#73-sponsor-firewalls","title":"7.3 Sponsor Firewalls","text":"<p>Allowed:</p> <ul> <li>RWE / Epidemiology</li> <li>HEOR</li> <li>Privacy/security teams</li> </ul> <p>Prohibited:</p> <ul> <li>Clinical operations</li> <li>Trial statisticians</li> <li>Medical monitors</li> <li>Protocol authors</li> </ul>"},{"location":"industry/#74-auditability","title":"7.4 Auditability","text":"<ul> <li>Logs of all transfers</li> <li>Access logs inside sponsor systems</li> <li>Annual review</li> </ul>"},{"location":"industry/#8-roles-and-responsibilities","title":"8. Roles and Responsibilities","text":""},{"location":"industry/#advocacy-group-data-controller","title":"Advocacy Group / Data Controller","text":"<ul> <li>Consent management</li> <li>De-identification</li> <li>Risk assessments</li> <li>DUA enforcement</li> </ul>"},{"location":"industry/#sponsor","title":"Sponsor","text":"<ul> <li>Maintain firewalls</li> <li>Control internal access</li> <li>Avoid trial contamination</li> </ul>"},{"location":"industry/#oversight-committee-optional","title":"Oversight Committee (Optional)","text":"<ul> <li>Review high-risk cases</li> <li>Advise on ethics and expectations</li> </ul>"},{"location":"industry/#9-data-sharing-checklist","title":"9. Data-Sharing Checklist","text":""},{"location":"industry/#purpose","title":"Purpose","text":"<ul> <li> Purpose defined</li> <li> Sponsor trial activity identified</li> <li> Regulatory vs non-regulatory use clarified</li> </ul>"},{"location":"industry/#data-characteristics","title":"Data Characteristics","text":"<ul> <li> Type</li> <li> Aggregation level</li> <li> Timing</li> <li> Granularity</li> </ul>"},{"location":"industry/#consent-privacy","title":"Consent &amp; Privacy","text":"<ul> <li> App consent allows sharing</li> <li> Re-identification risk reviewed</li> <li> HIPAA/GDPR compliance documented</li> </ul>"},{"location":"industry/#trial-integrity","title":"Trial Integrity","text":"<ul> <li> Overlap with trial evaluated</li> <li> Unblinding risk assessed</li> <li> Firewall documented</li> </ul>"},{"location":"industry/#governance","title":"Governance","text":"<ul> <li> DUA signed</li> <li> Named data recipients</li> <li> Prohibited teams identified</li> <li> Access controls set</li> <li> Logs enabled</li> </ul>"},{"location":"irb/","title":"IRB Documentation","text":"<p>Sample Content Only</p> <p>This page contains example language and placeholders designed to help registry teams build their own data sharing site. Please replace all placeholder text with details specific to your own project, policies, and governance requirements.</p>"},{"location":"irb/#irb-information","title":"IRB Information","text":"<p>This section describes the Institutional Review Board (IRB) or ethics approvals for the registry. Proper ethics oversight ensures that data collection and sharing comply with regulations and protect participants.</p> <p>IRB Approval: This registry study is approved by [Name of IRB or Ethics Committee]. - Protocol ID: [IRB protocol number or ID] - Approval Date: [Date of approval] - Renewal/Expiration: [If applicable, when does the approval expire or renew] - Consent: [Describe the consent provided by participants, e.g., \"All participants signed informed consent allowing their data to be used in de-identified form for research.\"]  </p> <p>Notes: The data shared through this site is de-identified and adheres to the conditions set by the IRB. Users of the data must agree to use it only for the approved purposes. If you have questions about the ethical use of the data, please contact the study coordinator or the IRB office at [contact info].</p> <p>Instructions: Update the details above with your actual IRB approval information. You can also attach or link to official documentation if appropriate (e.g., an IRB approval letter, if it can be shared). If multiple IRBs or approvals cover different parts of the data, list them all here.</p>"},{"location":"key_resources/","title":"Key Resources","text":"<p>Welcome to the Key Resources section. This page is designed to guide researchers, collaborators, and stakeholders to essential documents, tools, and educational materials related to patient registry research and responsible data sharing.</p>"},{"location":"key_resources/#your-organizations","title":"\ud83c\udfe2 Your Organization(s)","text":"<ul> <li>[Insert the name of your institution, sponsoring organization, or affiliated research network here]</li> </ul>"},{"location":"key_resources/#publications-from-our-registry","title":"\ud83d\udcc4 Publications from Our Registry","text":"<ul> <li>[List any publications, reports, or posters based on your registry\u2019s data. These can include DOI links, conference posters, or open-access PDFs]</li> </ul>"},{"location":"key_resources/#resources-and-educational-materials","title":"\ud83d\udcda Resources and Educational Materials","text":""},{"location":"key_resources/#book","title":"\ud83d\udcd8 Book","text":"<p>Guide to Real-World Data for Clinical Research By Danielle Boyce (ALS TDI) and Pavel Goriacko (Montefiore) \ud83d\udc49 Visit rwd.guide</p>"},{"location":"key_resources/#online-course","title":"\ud83c\udf93 Online Course","text":"<p>Introduction to OMOP: Your Frequently Asked Questions Answered Taught by Danielle Boyce (ALS TDI) and Pavel Goriacko (Montefiore) \ud83d\udc49 Enroll in the course</p>"},{"location":"key_resources/#external-links-and-policy-guides","title":"\ud83c\udf10 External Links and Policy Guides","text":"<ul> <li> <p>NIH Data Sharing Language Explained A plain-language guide to the NIH Data Management &amp; Sharing Policy and how it applies to patient registries.</p> </li> <li> <p>PubMed \u2013 Search for biomedical and life sciences literature.  </p> </li> <li>ClinicalTrials.gov \u2013 Information on publicly and privately supported clinical studies.  </li> <li>NIH Sharing Policies \u2013 Learn about federal data sharing policies.  </li> <li>FDA Real-World Evidence \u2013 Explore how real-world data are used in regulatory decisions.  </li> <li>EMA Real-World Evidence \u2013 European guidance on using real-world data sources.</li> </ul> <p>\ud83d\udca1 Need help customizing this page? See the How to Customize This Template guide.</p>"},{"location":"nih-data-sharing/","title":"Understanding NIH Data Sharing Language in Registry Agreements","text":"<p>\u26a0\ufe0f Disclaimer This page provides a general explanation of NIH data sharing expectations, particularly as they apply to patient registries. It is not legal or regulatory advice. Please consult your institution\u2019s IRB or regulatory officials to determine how these policies apply to your specific registry and data governance practices.</p>"},{"location":"nih-data-sharing/#the-inclusion-of-nih-data-sharing-language-in-data-use-agreements-is-essential-for-ensuring-compliance-with-federal-policy-protecting-patient-privacy-and-supporting-responsible-scientific-research","title":"The inclusion of NIH Data Sharing language in data use agreements is essential for ensuring compliance with federal policy, protecting patient privacy, and supporting responsible scientific research.","text":"<p>This page outlines why such language is important, what it requires of investigators, and how it applies specifically to patient registries such as those managed by [Registry Owner/Organization].</p>"},{"location":"nih-data-sharing/#1-nih-dms-policy-applies-to-all-nih-funded-research","title":"1. NIH DMS Policy Applies to All NIH-Funded Research","text":"<p>As of January 25, 2023, the NIH requires all funded research to include a Data Management &amp; Sharing (DMS) Plan.</p> <p>\ud83d\udd17 NIH Data Sharing Portal</p>"},{"location":"nih-data-sharing/#researchers-must","title":"Researchers Must:","text":"<ul> <li>Plan how scientific data will be managed and shared</li> <li>Specify data types, repositories, formats, access levels, and timelines</li> <li>Follow their DMS Plan as a condition of funding</li> <li>Justify any restrictions or limits on sharing</li> </ul> <p>If registry data are included, your DMS Plan must not violate privacy protections or registry policies.</p>"},{"location":"nih-data-sharing/#2-registry-data-often-cannot-be-openly-shared","title":"2. Registry Data Often Cannot Be Openly Shared","text":"<p>Even when de-identified, patient registry data may pose re-identification risks due to:</p> <ul> <li>Rare or small populations</li> <li>Geographic/demographic uniqueness</li> <li>Traceability through center affiliation</li> </ul> <p>Typically, consent forms do not permit public sharing of record-level data. Instead, data must be shared via controlled access mechanisms.</p> <p>NIH recognizes that legal or ethical concerns may limit sharing:</p> <p>\ud83d\udd17 Allowable limitations on data sharing (NIH)</p>"},{"location":"nih-data-sharing/#3-nih-projects-must-coordinate-with-the-registry","title":"3. NIH Projects Must Coordinate with the Registry","text":"<p>If a research project involves NIH funding:</p> <ul> <li>Notify the registry team (e.g., [datarequests@yourorg.org])</li> <li>Coordinate any changes requested by NIH reviewers</li> <li>Allow the registry to supply appropriate documentation</li> </ul> <p>This protects all parties and ensures NIH, HIPAA, and registry policies align.</p>"},{"location":"nih-data-sharing/#4-journals-expect-data-sharingbut-not-public-posting","title":"4. Journals Expect Data Sharing\u2014But Not Public Posting","text":"<p>Journals and funders now ask for:</p> <ul> <li>Data availability statements</li> <li>Clear access pathways for other researchers</li> </ul> <p>\u274c Do not post registry data on:   - GitHub   - Kaggle   - Dryad   - Figshare   - Supplemental materials in manuscripts</p> <p>Without checking with your Institutional Review Board first!</p> <p>\u2705 Instead, use NIH-compatible controlled access language:</p> <p>\u201cData may be available from [Registry Organization] upon request and contingent on approval by the [Registry Oversight Committee]. Access restrictions are in place to protect participant privacy.\u201d</p>"},{"location":"nih-data-sharing/#5-why-this-is-important-to-understand","title":"5. Why This Is Important to Understand","text":"Benefit Description \ud83d\udee1\ufe0f Protects Patients Prevents accidental re-identification \u2705 Complies with NIH Meets DMS Plan expectations \ud83e\udded Clarifies Roles The registry owner is the gatekeeper, not the external PI \ud83e\udde0 Avoids Mistakes Prevents premature or inappropriate data sharing \ud83e\udd1d Builds Trust Maintains public confidence in research participation"},{"location":"nih-data-sharing/#key-nih-resources","title":"Key NIH Resources","text":"<ul> <li>NIH Scientific Data Sharing Homepage</li> <li>NIH DMS Policy Summary</li> <li>NIH on Sharing &amp; Preservation Limitations</li> </ul>"},{"location":"researchers/","title":"Overview","text":"<p>Sample Content Only</p> <p>This page contains example language and placeholders intended to help registry teams set up their own data sharing site. Please replace all placeholder text with content specific to your own registry, governance policies, and workflows.</p>"},{"location":"researchers/#information-for-researchers","title":"Information for Researchers","text":"<p>This page explains how to request access to data from the patient registry and outlines key steps in the data use process.</p>"},{"location":"researchers/#data-use-agreement-ethics","title":"\ud83e\uddfe Data Use Agreement &amp; Ethics","text":"<p>Before data access can be granted, all investigators must:</p> <ul> <li>Review and agree to the Data Use Agreement</li> <li>Provide proof of IRB or ethics board approval</li> <li>Submit a complete data access application</li> </ul> <p>\u26a0\ufe0f Registries are encouraged to work with their IRB and legal teams to ensure that their Data Use Agreement reflects their governance model, privacy protections, and any regulatory requirements (e.g., HIPAA, GDPR).</p>"},{"location":"researchers/#data-access-process","title":"\ud83d\udd04 Data Access Process","text":""},{"location":"researchers/#data-access-process-overview","title":"\ud83d\udcca Data Access Process Overview","text":"\ud83e\udde9 Step \ud83d\udc64 Who \u2699\ufe0f What Happens \ud83d\udd04 Outcome / Next Step 1\ufe0f\u20e3 \ud83e\uddd1\u200d\ud83d\udd2c Investigator Submits data access request \u27a1\ufe0f Sent to Registry Staff 2\ufe0f\u20e3 \ud83d\uddc2\ufe0f Registry Staff Reviews request \ud83d\udd01 Requests info \ud83d\udd38or\ud83d\udd38 forwards to DAC 3\ufe0f\u20e3 \ud83e\uddd1\u200d\u2696\ufe0f DAC Reviews application \u2705 Approve \ud83d\udd38 \u274c Reject \ud83d\udd38 \ud83d\udd01 Request Revisions 4\ufe0f\u20e3 (a) \ud83e\uddd1\u200d\u2696\ufe0f DAC Approves request \u2705 IRB confirmed &amp; DUA sent by Registry 4\ufe0f\u20e3 (b) \ud83e\uddd1\u200d\u2696\ufe0f DAC / Investigator Requests revisions \ud83d\udcdd Investigator revises &amp; resubmits to DAC 4\ufe0f\u20e3 (c) \ud83e\uddd1\u200d\u2696\ufe0f DAC Rejects request \ud83d\udced Investigator notified 5\ufe0f\u20e3 \ud83d\uddc2\ufe0f Registry Staff Confirms IRB + Receives DUA signature \ud83d\udce6 Prepares data 6\ufe0f\u20e3 \ud83d\uddc2\ufe0f Registry Staff Prepares &amp; sends data \ud83d\udce4 Data delivered to Investigator 7\ufe0f\u20e3 \ud83e\uddd1\u200d\ud83d\udd2c Investigator Performs analysis &amp; drafts manuscript \ud83d\udce8 Sends manuscript to registry 8\ufe0f\u20e3 \ud83d\uddc2\ufe0f Registry Staff Reviews manuscript (within 2 weeks) \u2705 Approve or \u270f\ufe0f Request changes 9\ufe0f\u20e3 \ud83e\uddd1\u200d\ud83d\udd2c Investigator Revises publication if needed \ud83d\udcda Final publication with citation"},{"location":"researchers/#what-to-submit","title":"\ud83d\udccb What to Submit","text":"<p>A complete data access request typically includes:</p> <ul> <li>A brief research proposal or study aims  </li> <li>A list of requested data elements or cohorts  </li> <li>IRB/ethics approval letter  </li> <li>Signed Data Use Agreement  </li> <li>Timeline and any expected funding source  </li> <li>Named collaborators and data security plans  </li> </ul> <p>\ud83d\udca1 Registries may include a downloadable submission template or link to an online data access portal.</p>"},{"location":"researchers/#oversight-and-review","title":"\ud83d\udee1\ufe0f Oversight and Review","text":"<p>All data requests are evaluated by the Data Access Committee (DAC) to ensure:</p> <ul> <li>Scientific merit and feasibility  </li> <li>Compliance with ethical standards  </li> <li>Appropriate use of sensitive or identifiable fields  </li> <li>Data use aligns with the registry's goals and participant consent</li> </ul> <p>We have created a sample Data Access Committee (DAC) Standard Operating Procedure (SOP) here and DAC evaluation rubric, here.</p>"},{"location":"researchers/#after-approval","title":"\ud83e\udde8 After Approval","text":"<p>Once your application is approved:</p> <ul> <li>You\u2019ll receive a copy of the finalized DUA  </li> <li>The registry team will coordinate access or data delivery  </li> <li>You may be asked to provide periodic updates or reports  </li> <li>Destruction of data may be required after study completion  </li> </ul> <p>For guidance, contact: datarequests@yourdomain.org</p>"},{"location":"researchers/#need-help","title":"\ud83d\udcdd Need Help?","text":"<p>Visit the How to Customize This Template page for help editing this content to match your own workflow and policies.</p>"},{"location":"survey/","title":"\ud83d\udccb Registry Data Access User Survey","text":"<p>Disclaimer</p> <p>This is sample content only. Please consult your IRB or data governance committee before using this form in a live environment.</p> <p>Thank you for your interest in accessing this patient registry data. To help us understand your needs and ensure responsible data sharing, please complete the following questionnaire.</p>"},{"location":"survey/#1-intended-use","title":"\ud83e\udde0 1. Intended Use","text":"<p>1.1 What is the title or primary aim of your research project? Example: \u201cIdentifying phenotypic clusters in X disease and linking to gene expression data.\u201d </p> <p>Your answer:</p> <p>1.2 What are your primary research questions or use cases? (Select all that apply):</p> <ul> <li> Descriptive statistics  </li> <li> Epidemiology  </li> <li> Comparative effectiveness  </li> <li> Health services research  </li> <li> Clinical trial design or feasibility  </li> <li> Genomic/Omic integration or phenotype-genotype analysis  </li> <li> Biomarker discovery or validation  </li> <li> Multi-modal data analysis (e.g., combining clinical and imaging or biospecimen data)  </li> <li> Linkage with biospecimen or biobank data  </li> <li> Algorithm development (e.g., phenotyping, prediction models)  </li> <li> Policy or access equity analysis  </li> <li> Other (please specify):   <p>Your answer:</p> </li> </ul>"},{"location":"survey/#2-tools-technical-preferences","title":"\ud83e\uddf0 2. Tools &amp; Technical Preferences","text":"<p>2.1 What analysis tools or environments do you prefer to use? (Select all that apply):</p> <ul> <li> R  </li> <li> Python / Jupyter notebooks  </li> <li> SAS  </li> <li> SPSS  </li> <li> Stata  </li> <li> Excel / CSV  </li> <li> SQL / Relational database  </li> <li> Bioinformatics tools (e.g., Galaxy, Bioconductor)  </li> <li> HPC or cloud-based workflows (e.g., Terra, DNAnexus)  </li> <li> Other (please specify):   <p>Your answer:</p> </li> </ul> <p>2.2 Are you familiar with working in a secure remote analysis environment (enclave)?</p> <ul> <li> Yes, I regularly use enclaves or cloud-based notebooks  </li> <li> Somewhat \u2013 I\u2019ve used them occasionally  </li> <li> No \u2013 I prefer local file downloads or offline analysis</li> </ul>"},{"location":"survey/#3-data-refresh-and-timeline","title":"\ud83d\udd01 3. Data Refresh and Timeline","text":"<p>3.1 How frequently would you need data updates, if at all?</p> <ul> <li> One-time snapshot  </li> <li> Quarterly  </li> <li> Biannually  </li> <li> Annually  </li> <li> Other (please specify):   <p>Your answer:</p> </li> </ul> <p>3.2 Will your project evolve over time (e.g., need new variables or patient cohorts)?</p> <ul> <li> Yes  </li> <li> No  </li> <li> Not sure</li> </ul>"},{"location":"survey/#4-data-scope-and-needs","title":"\u2795 4. Data Scope and Needs","text":"<p>4.1 Is the minimal shared dataset likely to meet your needs? (Minimal dataset includes core demographic, clinical, and visit variables.)</p> <ul> <li> Yes  </li> <li> No \u2013 I\u2019ll likely request additional data  </li> <li> Not sure  </li> </ul> <p>4.2 If requesting additional data, which categories are of interest? (Check all that apply):</p> <ul> <li> Longitudinal clinical data  </li> <li> Imaging metadata or derived variables  </li> <li> Genomic, transcriptomic, proteomic, or metabolomic data  </li> <li> Patient-reported outcomes  </li> <li> Visit-level or procedure-level detail  </li> <li> Geolocation or provider-level information  </li> <li> Other (please describe):   <p>Your answer:</p> </li> </ul>"},{"location":"survey/#5-compliance-and-review","title":"\ud83d\udd10 5. Compliance and Review","text":"<p>5.1 Has your institution required or initiated a Data Use Agreement (DUA)?</p> <ul> <li> Yes  </li> <li> No  </li> <li> Not sure  </li> </ul> <p>5.2 What is the status of your IRB or ethics board approval?</p> <ul> <li> Approved  </li> <li> Submitted, awaiting decision  </li> <li> Not yet submitted  </li> <li> Exempt / not applicable (please explain):   <p>Your explanation:</p> </li> </ul>"},{"location":"survey/#6-use-of-biospecimens-or-linkage","title":"\ud83e\uddec 6. Use of Biospecimens or Linkage","text":"<p>6.1 Will you be requesting data to be linked with biological samples or a biobank?</p> <ul> <li> Yes \u2013 we plan to request biospecimen linkage  </li> <li> No \u2013 we will use registry data only  </li> <li> Not sure  </li> </ul> <p>6.2 If yes, what types of biospecimen data will be used or integrated? (e.g., blood, saliva, tumor tissue, omics, sequencing platform, etc.) </p> <p>Your answer:</p>"},{"location":"survey/#7-additional-information","title":"\ud83d\udcdd 7. Additional Information","text":"<p>7.1 Is there anything else you'd like us to know about your project scope, collaborators, or data needs? </p> <p>Your answer:</p> <p>Please return this completed form to [datarequests@yourregistry.org] or submit it via our data access portal.</p>"}]}